As AtheroGenics prepares to wrap up phase 3 trial sites for its lead atherosclerosis compound, small molecule AGI-1067, the future could suddenly become very bright for this tiny research company ...

We could build an AI that demonstrates generalized, human-level intelligence within three to eight years — which may open the door to a "super intelligence" in a very short space of time.